Type6 Therapeutics
3 known investors
Type6 Therapeutics is a drug-discovery company developing kinase inhibitors that target the inactive OFF-state of kinases to improve selectivity and durability against cancers that evade existing therapies. Its lead program is a CDK2 inhibitor (CDK2i), with plans to expand into additional kinase targets across the human kinome.
Founders & leadership
GK
Gert KissCo-founder & CEO
AB
Alexander BridgesCo-founder, CSO, VP Chemistry
JO
Jeffrey OhrenCo-founder, VP Biology
MO
Mihail ObroceaHead of Development
RS
Robert SonsHead of Operations
Investors · 3
Frequently asked questions
- What does Type6 Therapeutics do?
- Type6 Therapeutics is a drug-discovery company developing kinase inhibitors that target the inactive OFF-state of kinases to improve selectivity and durability against cancers that evade existing therapies. Its lead program is a CDK2 inhibitor (CDK2i), with plans to expand into additional kinase targets across the human kinome.
- Who founded Type6 Therapeutics?
- Type6 Therapeutics was founded by Gert Kiss, Alexander Bridges, Jeffrey Ohren.
- Who are Type6 Therapeutics's investors?
- Type6 Therapeutics's investors include Artis Ventures, OMX Ventures, BoxOne Ventures.